New anesthetic approach in glaucoma surgery: “Underbleb” subtenonian anesthesia and its influence in medium term outcome

Díaz, M. Martínez; López, Francisca; Amorós, N. Puerto; Valladares, Amparo

doi:10.1016/j.oftale.2020.01.009

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Besides, among the anterior techniques (topical, subconjunctival, and sub-Tenon), the anterior sub-Tenon provides the higher amount of akinesia. 36 Even though some studies have reported the advantage of the anterior sub-Tenon technique on the site of surgery due to the atraumatic dissection of the Tenon capsule 37 others have proposed the opposite, an increased risk of bleeding and associated fibrosis. 38 In our opinion, the less the manipulation of the conjunctiva, the lower the inflammatory response will be, a main reason to locate the anesthesia away from the site of surgery.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma

Barberá¹,

Galdón²,

Magro³

et al. 2022

Journal of Glaucoma

View full text Add to dashboard Cite

Précis: The Preserflo Microshunt (PSM) is a safe and effective glaucoma microfiltering implant that significantly reduces the intraocular pressure (IOP), either alone or in combination with phacoemulsification, during the first year after surgery. Purpose:The purpose of this study was to assess the safety and efficacy of the PSM for the treatment of open angle glaucoma with 0.2 mg/mL mitomycin C, either alone or in combination with cataract surgery. Methods:A retrospective, open-label study of 64 eyes with primary open angle glaucoma that underwent PSM implantation and were followed up for at least 9 months. Success was defined as IOP 6-17 mm Hg and a reduction of at least 20%, complete without hypotensive medication, and qualified with medication. Safety was assessed by the incidence of adverse events. Secondary endpoints included mean hypotensive medications, visual acuity, and incidence of needling and surgical revision.Results: A total of 51 eyes underwent PSM alone and 13 underwent PSM+phacoemulsification. In the overall population of the study, the mean IOP was significantly reduced from 22.03 ± 0.7 mm Hg at baseline to 12.7 ± 0.4 mm Hg at the final visit, P < 0.0001 (mean follow-up: 11 ± 1.4 mo). The IOP was significantly reduced in both groups (P < 0.0001). Ocular hypotensive medication was reduced significantly from 2.7 ± 0.7 to 0.2 ± 0.5 (P < 0.0001). No significant differences were found in IOP-lowering medication between groups (PSM alone, 0.2 ± 0.08; PSM+phacoemulsification, 0.1 ± 0.1; P = 0.2). At the final visit, 70.3% were considered as complete success and 12.5% as qualified success. The most common adverse event was clinical hypotony (7.8%) followed by hyphema (4.7%), and anterior chamber reformation (1.6%). Overall, 1.6% required needling and 15.6% surgical revision to restore the flow. Conclusion:Glaucoma surgery with the PSM and mitomycin C was efficacious and safe in the short term, either alone or in combination with cataract surgery, and may be considered a surgical option for lowering IOP in primary open angle glaucoma.

show abstract